Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Trientine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Trientine hydrochloride overview

trientine hydrochloride is under development for treatment of ischemic heart disease, chronic heart failure, myocardial infarction, left ventricular ejection fraction and amyloidosis. It is administered by oral route. The drug candidate is a therapeutic copper binding molecule.

For a complete picture of Trientine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.